Based in the Nice Côte d’Azur Metropolis, Virbac is a major player in the field of animal health.
In 2023, the company celebrated 30 years of presence in the Asia-Pacific region and 40 years of operations in Spain, announcing several strategic developments. Including the creation of a subsidiary in Ireland and the acquisition of its distributor in the Czech Republic and Slovakia.
Total acquisition of Globion by Virbac
On June 21, 2024, Virbac finalized the acquisition of the minority stake in Globion, thereby increasing its participation to 100%. This transaction follows the acquisition of a majority stake of 74% completed on November 1, 2023.
Founded in 2005, Globion is a joint venture between Suguna Group, a major player in the Indian poultry industry, and Lohmann Animal Health, a German company specializing in poultry vaccines.
Globion has developed strong expertise in the manufacturing of live and inactivated vaccines for avian pathogens.
Strengthening Virbac’s position in the Indian market
Virbac, based in the Nice Côte d’Azur Metropolis, is thus strengthening its presence in the Indian animal health market, a rapidly expanding sector.
Located in Hyderabad with around 120 employees, Globion generated revenue of approximately €12 million in 2023.
This acquisition enables Virbac to consolidate its position in India, the world’s most populous country, and to complement its product portfolio for the poultry industry.
Strategic expansion in Asia-Pacific
This acquisition is part of a series of strategic developments for Virbac, including the creation of a subsidiary in Ireland and the acquisition of its distributor in the Czech Republic and Slovakia Virbac also celebrated 30 years of presence in the Asia-Pacific region and 40 years of operations in Spain.
In October 2023, Sébastien Huron, CEO of Virbac, highlighted: “We are extremely pleased and honored to welcome the Globion team into our Virbac family. This acquisition illustrates Virbac’s 2030 vision and its ambition to grow through ‘programmatic’ acquisitions by investing in vaccines, a key strategic axis of development, by strengthening our leadership position in India, the most populous country in the world, and by complementing our portfolio targeting the dynamic and promising poultry market. We will fully commit to the Globion teams and provide them with additional resources to help them give their best. With the teams from Suguna and Globion, we are united by the common ambition to create long-term value for our customers and to build, through innovation, a competitive product portfolio to support the poultry industry in India and abroad.”
Healthtech / Biotech – Nice Côte d’Azur France
- Obesity: French first at Nice University Hospital
- Team Nice Côte d’Azur at the Van Lanschot Kempen Life Sciences Conference 2026
- Launch of the AZUR Territorial Research Entity to advance clinical research on the French Riviera
- BIO-Europe Spring 2026 : meet with Team Nice Côte d’Azur
- Eurobiomed: more than €300 million secured in 2025 in the Sud and Occitanie regions by Eurobiomed member healthcare companies
- Artificial intelligence: Team Nice Côte d’Azur mobilized for an AI Business Tour and WAICF 2026
- Nice University Hospital signs an international cooperation agreement with Emirates Hospitals Group (Dubai)
- Caranx Medical, a Nice-based cardiac robotics MedTech startup, set to be acquired for €16.6 million
- AVC continues its expansion with a consolidated base in the Côte d’Azur
- New medical governance at CHU de Nice
